The presence of WNT/β-catenin signaling in circulating extracellular vesicles (EVs) [90], and surface representation of PD-L1 by EVs secreted from tumor cells [91] are all indicative of a possibility for application of EVs in cancer immunotherapy targeting both signaling. This evidence concerns the gene CD274 and cancer.